enGene Holdings Inc. (ENGN) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Saint-Laurent, Canada. El CEO actual es Ronald H. W. Cooper.
ENGN tiene fecha de IPO 2022-02-01, 56 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $397.27M.
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
